Petitprez et al. have reported that STS patients with significant immune infiltration exhibit increased expression of immunological checkpoints, such as PD-L1, PD-L2, CTLA-4, and TIM-3, and better clinical outcomes (Petitprez et al., 2020). The gene discussed is PDCD1LG2; the disease is telomere syndrome.